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Introduction
Rheumatoid arthritis (RA) is a widespread (prevalence
0.5–1%), chronic inflammatory disease that is localized pri-
marily in the joints and has several pathological features of
autoimmune disease. The disease is characterized by cellu-
lar infiltration in synovial tissue, pannus formation, and both
cartilage and bone erosion. The cytokine profile of RA
joints reveals an abundance of macrophage and fibroblast
cytokines such as tumour necrosis factor (TNF)-α, IL-1,
granulocyte–macrophage colony-stimulating factor and
IL-6, along with smaller amounts of T-cell products. TNF-α
has proved pivotal among these cytokines, and the devel-
opment of protein-based anti-TNF-α therapeutics, including
Remicade® (Centocor Inc., Malvern, PA, USA) and Enbrel®
(Immunex Corporation, Thousand Oaks, CA, USA), which
inhibit joint inflammation and prevent joint destruction, rep-
resent a significant advance in the treatment of RA [1].
Importantly, they have proved effective in a high proportion
of patients who do not respond to other therapies [2].
Drawbacks to these protein therapies are the requirement
for repeated administration by injection and the high cost
of treatment (US$13000/patient per year).
CIA = collagen-induced arthritis; CII = collagen type II; EGFP = enhanced green fluorescent protein; ELISA = enzyme-linked immunosorbent assay;
IFN = interferon; IL = interleukin; PBS = phosphate-buffered saline; RA = rheumatoid arthritis; dTNFR = dimeric TNFR2; TNF = tumour necrosis
factor; TNFR = tumour necrosis factor receptor.
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Abstract
Tumor necrosis factor (TNF)-α is produced by cells of the
immune system and is a key mediator in immune and
inflammatory reactions. Through interaction with widely
expressed receptors (TNF receptor 1 and TNF receptor 2),
TNF-α is able to orchestrate the expression of a range of
downstream proinflammatory molecules. Over the past decade
novel biologics that inhibit TNF-α have been developed as
extremely effective treatments for rheumatoid arthritis.
Structurally, these biologics are antibodies, or TNF receptors
on an antibody backbone that bind TNF-α directly and are
delivered to patients by repeated injection. Gene therapy offers
an improved approach to delivering biologics as a single
administration of their encoding genetic material. In the present
study we demonstrate the therapeutic effect of a small
molecular weight dimeric TNF receptor 2 (dTNFR)
constitutively expressed from plasmid DNA, delivered
intramuscularly with electroporation, after disease onset in a
collagen-induced arthritis model. Regulated promoters that
enable the production of a transgene to be controlled are more
suited to the application of gene therapy in the clinic.
Regulated expression of dTNFR from the plasmid pGTRTT was
also therapeutic in the mouse collagen-induced arthritis model
when the inducer doxycycline was also administered, whereas
no therapeutic effect was observed in the absence of
doxycycline. The therapeutic effect of dTNFR expressed from a
constitutive or regulated plasmid was dependent on the degree
of disease activity at the time of DNA injection. The
observations of this study are considered with regard to the
disease model, the magnitude of gene regulation, and the path
to clinical application.
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We previously constructed dTNFR, which is a smaller
inhibitor of TNF-α than existing biologics and consists of
two extracellular subunits of the human TNF receptor
TNFR2 connected by a short flexible serine glycine linker
[3]. This molecule inhibits TNF-α in vitro [3] and has been
shown to inhibit disease when delivered before onset in
arthritis models [4] and was also therapeutic in a model of
multiple sclerosis [5].
Gene therapy is potentially an improvement on protein
therapy. Following the appropriate delivery of genetic
material, the body’s own cells are able to produce a
protein therapeutic. Delivery of genetic material can be
achieved with viruses such as adenoviruses, which give
transient high-level expression of transgenes and have
been widely applied in gene therapy in experimental RA
models. Alternatively, retroviruses that integrate trans-
genes into the genome of dividing cells have proved effec-
tive tools in experimental ex vivo strategies in arthritis
models [6]. The initial enthusiasm for viral vectors as can-
didate vehicles for gene delivery was tempered by safety
concerns in clinical trials: first the death of a patient follow-
ing administration of adenovirus [7]; and second the
development of leukaemia in severe combined immuno-
deficient patients who received retrovirally transduced
haematopoietic stem cells [8].
Plasmid DNA isolated from bacteria has no innate mecha-
nism of cell entry or propagation, and does not encode
accessory proteins or integrate into the genome, but it has
the potential to be an efficient vehicle for gene delivery in
vivo when administered by intramuscular injection. First
reported by Wolff and coworkers in 1990 [9], injection of
plasmid DNA into mouse skeletal muscle results in long-
term (at least 2 months) transgene expression. More
recently it was shown that when muscle was electro-
porated after DNA injection the efficiency of transfection
was further enhanced by a factor of 100-fold, with trans-
gene expression persistent up to 1 year [10]. Plasmid
DNA also has the advantage of being very stable and both
easy and cheap to produce in large quantities.
Ideally, gene therapy for a chronic disease such as RA will
permit long-term production of a therapeutic molecule, so
reducing the need for repeat administration. In combina-
tion with regulated promoter systems, therapeutic levels of
a molecule are produced, so avoiding excess (toxicity) and
inadequate (no effect) production, and this also provides a
means by which to terminate expression in the event of
adverse effects. Principal among the transcriptionally regu-
lated systems that have been developed are the tetracy-
cline ‘off’ [11], ‘on’ [12] and ‘repressor’ [13] systems, and
the ecdysone [14], rapamycin [15] and streptogramin [16]
systems, which are all two- or three-component systems
that utilize a small molecule to regulate the activity of a
responsive promoter (for review [17]). The tetracycline
regulated systems have the inherent advantage that tetra-
cycline and several derivatives have well defined
pharmacokinetics and pharmacodynamics [18]. We and
others previously combined the components of the tetra-
cycline ‘on’ system into a self-contained autoregulated
plasmid vector [19].
In the present study we constructed plasmids encoding
dTNFR from constitutive and regulated promoters, from
which the expression of dTNFR was characterized in vitro.
Function of the vectors was demonstrated in vivo after
intramuscular delivery, and we examined the therapeutic
effect of dTNFR expressed constitutively or in a regulated
manner from plasmid DNA administered after the onset of
disease in the mouse collagen-induced arthritis (CIA)
model.
Materials and method
DNA and cloning
The vectors pGT, pGTL, pGTE, pGTRTL, and pGCMV
were previously reported [19]. The construct pGTTRD,
which encodes dTNFR from a Ptet, was constructed by
removing the dTNFR sequence from the construct pTRIP
[3] by restriction with NcoI filled in with Klenow, and cut
with XbaI, and inserting it into pGT restricted with EcoRV
and XbaI. The self-contained regulated plasmid pGTRTT
encoding dTNFR was then contructed by removing the
Ptet–dTNFR cassette from pGTTRD by restriction with
Nhe1and PflMI and ligating it into pGTRTL restricted with
the same enzymes. The plasmid pcdTNFR, in which dTNFR
is located downstream of a cytomegalovirus promoter, was
constructed by removing the dTNFR gene from pGTTRD
by restriction with HindIII and XbaI and inserting it into
pcDNA3 (Invitrogen, Leek, The Netherlands) restricted with
the same enzymes.
A control construct pGTRTEmpty was also prepared,
which retained all the elements of pGTRTT except the
dTNFR gene. pGTRTE is an autoregulatory plasmid from
which enhanced green fluorescent protein (EGFP) expres-
sion is regulated, and it was constructed by removing the
Ptet–EGFP cassette from pGTE by restriction with XhoI
and PflMI and inserting it into pGTRTL restricted with the
same enzymes. The EGFP gene was removed from
pGTRTE by restriction with ClaI and re-ligation of the
plasmid formed pGTRTEmpty.
The plasmid pcLuc+, which encodes luciferase from a
cytomegalovirus promoter, was constructed by removing
the improved luciferase gene (Luc+) from pGL3 Basic
(Promega Corp., Madison, WI, USA) with the restriction
enzymes XhoI and XbaI and inserting the gene into
pcDNA3 restricted with the same enzymes.
Plasmids were expanded in Escherichia coli DH5α except
autoregulatory vectors, which were propagated in E. coli
R105
DH 21. Plasmid DNA was purified using the Plasmid
Mega Kit (Qiagen Ltd, Crawley, UK), or when required for
injection into mice the EndoFree™ Plasmid Mega Kit
(Qiagen Ltd) was used. All plasmids that were used in
expression studies are depicted schematically in Fig. 1.
Cells
Cos-7 (SV40 transformed monkey kidney fibroblast,
ECACC cat. no. 87021302) cells were cultured in Dul-
becco’s modified Eagle’s medium (BioWhittaker, Woking-
ham, UK) supplemented with 10% foetal calf serum
(Gibco BRL, Paisley, UK), glutamine (2 mmol/l; BioWhit-
taker), penicillin (100 U/ml; BioWhittaker) and strepto-
mycin (100 µg/ml; BioWhittaker).
Transfections
Transfections were performed using the calcium phos-
phate precipitation method used previously [19]. Cos-7
cells were plated on 12-well plates at a density of
0.4 × 106/well and were transfected the next day with 2 µg
DNA. Cells were subjected to an osmotic shock on the
second day, after which fresh media was added with or
without doxycycline at a concentration of 1 µg/ml. Super-
natants were collected 24 or 48 hours later and levels of
dTNFR were determined by ELISA.
In vivo electroporation
Mice were treated according to approved UK Home
Office and institutional guidelines. Naïve or arthritic DBA/1
mice were injected intraperitoneally with the muscle relax-
ant Hypnorm™ (Janssen Animal Health, Janssen Pharma-
ceuticals, Beerse, Belgium) and were anaesthetized with
halothane (Concord Pharmaceuticals Ltd, Dunmow, UK)
using Boyle’s apparatus (British Oxygen Company,
London, UK). The fur covering the right quadracep was
shaved and the exposed skin sprayed with disinfectant.
Endotoxin-free plasmid for injection was prepared in a
solution of 0.9% NaCl at a concentration of 250 µg/ml for
reporter gene studies or 833 µg/ml for therapeutic
studies. DNA (20 µl) was injected intramuscularly at three
sites, and Camcare ECG gel (Camcare Gels, Mepal, UK)
was then applied to the surface of the skin. Caliper elec-
trodes 384L (BTX Instrument Division, Harvard Apparatus
Inc., Holliston, MA, USA) were applied transversely across
the quadriceps and the muscle was electroporated with
four pulses at 200 V/cm and 20 ms duration at a fre-
quency of 2 Hz using a BTX Electro Square Porator ECM
830 (Harvard Apparatus Inc.). The polarity of the elec-
trodes was then reversed and the procedure repeated.
Regulated expression of luciferase in vivo
Regulated expression of luciferase from pGTRTL was
assessed in DBA/1 mice following intramuscular injection
and electroporation. Expression of luciferase was compared
with control plasmids pGmCMV, pGTL and pGCMV.
Plasmid DNA was injected intramuscularly into 10- to
12-week-old naïve DBA/1 mice along with electroporation.
Luciferase expression in control groups was assessed
4 weeks after DNA injection, when animals were killed and
muscle tissue was snap frozen until further processing.
The plasmid pGTRTL was injected into 30 mice, which
were divided into six groups of five animals. These mice
received normal drinking water for 2 weeks, and then two
groups were given distilled water containing 10%
sucrose, three groups drank doxycycline 200 µg/ml and
one group was given doxycycline 2 mg/ml; the doxycycline
solutions were prepared in distilled water containing 10%
sucrose. All drinking bottles were wrapped in aluminium
foil and were renewed every 2–3 days. After a further
2 weeks a group of animals from each treatment group
was killed and the quadriceps muscles dissected and
snap frozen. In order to analyze the reversal of gene induc-
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Figure 1
Expression plasmids used in this study. Numbers in parenthesis
represent the length of each vector in base pairs. , SV40 early/late
poly A signal; H17009, β-globin poly A signal; , downstream SV40
untranslated region. CMV, immediate–early enhancer/promoter;
dTNFR, dimeric human tumour necrosis factor receptor 2; Luc,
luciferase gene; Luc+, improved luciferase gene; Ptet, tetracycline
responsive promoter; rtTA, reverse tetracycline transactivator.
tion from pGTRTL following the removal of doxycycline, a
group of animals that had received doxycycline 200 µg/ml
were switched to the sucrose drink. Three days later the
remaining mice were killed and muscles collected as for
the others.
Luciferase assay
Luciferase activity in transfected muscle was determined
using the luciferase assay system (Promega Corp.).
Quadriceps muscles dissected from treated mice were
snap frozen and stored at –70°C. Frozen muscle was
processed by a method similar to that described by Har-
tikka and coworkers [20]. Briefly, they were first crushed in
a freezer mill (model 6750; Spex Centriprep Inc.,
Metuchen, NJ, USA) and the powder was transferred to
an Eppendorf tube containing 0.5 ml reporter lysis butter.
The suspension was then subjected to three rounds of
freeze thawing, followed by 15 min of vortexing at 4°C.
Samples were centrifuged (13 000 rpm for 5 min) and the
lysate collected; pelleted material was resuspended in a
second aliquot of lysis buffer and was subjected to the
15 min of vortexing followed by centrifugation. The second
lysate was combined with the first and luciferase activity
was determined in a 20 µl aliquot of the sample, which
was automatically mixed with 100 µl of luciferase assay
substrate, and light emission measured using a MLX
Microtiter® Plate Luminometer (Dynex Technologies Inc.,
Chantilly, VA, USA). Protein concentrations of muscle
lysate were determined using the Bradford protein assay
(Bio-Rad Laboratories Inc., Hercules, CA, USA) and
values for luciferase activity were expressed as relative
light units per microgram of protein.
Collagen-induced arthritis
DBA/1 mice aged between 10 and 12 weeks were admin-
istered Hypnorm™ (0.1 ml, intraperitoneally) and were
shaved at the base of the tail. Bovine collagen type II (CII)
was emulsified with complete Freund’s adjuvant at a final
concentration of 2 mg/ml, and a total of 0.1 ml was
injected intradermally at three sites at the base of the tail.
Twenty-one days later, a booster (0.1 ml) consisting of CII
emusified with incomplete Freund’s adjuvant (2 mg/ml)
was injected intradermally across three sites at the tail
base. A further 3 days later animals were injected with
lipopolysaccharide (40 µg in 0.1 ml phosphate-buffered
saline [PBS]; E. coli serotype 055:B5; Sigma-Aldrich Co.
Ltd, Poole, UK) intraperitoneally to synchronize disease
[21]. The development and progression of arthritis was
monitored every 2–3 days and was assigned a clinical
score based on visual signs of arthritis (0.25 = swelling in
a single digit; 0.5 = swelling in more than one digit;
1 = swelling and erythema of the paw; 2 = swelling of the
paw and ankle; 3 = complete inflammation of the paw; the
maximum score for each mouse was therefore 12) and the
thickness of hind paws was measured using POCO 2T
calipers (Krœplin Längenmesstechnik, Schlüchtern,
Germany). Mice were monitored until 40 days after immu-
nization, when they were killed and blood was collected
for serum and draining lymph nodes were collected for
assessment of stimulated cytokine secretion.
Three days after injection of lipopolysaccharide (day 27),
animals were assessed for development of arthritis.
Animals with a clinical score of 0.5 or above were used in
gene therapy experiments and were administered 50 µg of
DNA intramuscularly in 60 µl at three sites and were elec-
troporated utilizing conditions described above.
Cytokine expression from draining lymph node cells
Inguinal draining lymph nodes were removed from mice on
day 40 after immunization. Incisions were made in the
lymph nodes and cells were dispersed using a nylon cell
strainer (70 µm; Becton Dickinson Labware, Franklin
Lakes, NJ, USA). Cell suspensions were centrifuged and
resuspended at 3 × 106/ml in Dulbecco’s modified Eagle’s
medium supplemented with 10% foetal calf serum, gluta-
mine (2 mmol/l), penicillin (100 U/ml) and streptomycin
(100 µg/ml). Cells (6 × 105 cells in 200 µl) were aliquoted
into wells in a 96-well microtitre plate and were stimulated
with either CII (50 µg/ml) or ConA (2.5 µg/ml; Sigma-
Aldrich Co. Ltd) for 48 hours, after which supernatants
were collected and stored at –80°C until measurements
of IFN-γ or IL-4 were performed by ELISA (see below).
Detection of dTNFR and antihuman TNFR2 by ELISA
To measure levels of dTNFR, a microtitre plate was coated
with 50 µl of a mouse monoclonal antihuman TNFR2 (R&D
Systems, Minneapolis, MN, USA) at 4 µg/ml overnight at
4°C. Plates were washed with PBS and then blocked with
200 µl of 2% casein solution in PBS for 1 hour at room
temperature. Plates were washed with PBS containing
0.05% Tween 20 (PBS/Tween) before incubation of stan-
dards (50 µl of human TNFR2 [R&D Systems] 1 pg/ml to
1 µg/ml) and samples (50 µl of serum or culture medium)
for 3 hours at room temperature. Plates were washed
extensively with PBS/Tween before incubation with 50 µl
of biotinylated goat antihuman TNFR2 (R&D Systems) at a
concentration of 100 ng/ml for 1 hour at room tempera-
ture. Signal was detected using the TMB microwell sub-
strate system (Kirkegaard and Perry Laboratories Inc.,
Gaithersburg, MD, USA) and the reaction stopped by
addition of 4 mol/l sulphuric acid (100 µl) and absorbance
measurements were performed at 450 nm using an EL
312e microplate biokinetics reader (Bio-Tek Instruments
Inc., Winooski, VT, USA). The detection limit of this ELISA
was 10 pg/ml.
In order to determine the immunogenicity of the dTNFR,
an ELISA was also performed to measure antihuman
TNFR2 in the sera from experimental mice. Microtitre
plates were coated overnight at 4°C with 50 µl of human
TNFR2 (2 µg/ml). Plates were washed with PBS and then
Arthritis Research & Therapy    Vol 6 No 2 Gould et al.
R106
blocked with 2% casein solution in PBS for 2 hours at
room temperature. Plates were then washed with
PBS/Tween and then incubated with serum (diluted
1 : 500) or dilutions of control mouse monoclonal antibody
(R&D Systems: 1 µg/ml to 0.1 pg/ml) for 3 hours at room
temperature. Plates were again washed with PBS/Tween
and bound antibody was detected using peroxidase
conjugated sheep antimouse IgG (The Binding Site, Birm-
ingham, UK), and after 1 hour the signal was developed
and measured as described above. The control mouse
monoclonal antibody was detected down to a concentra-
tion of 0.1 pg/ml.
ELISA for detection of anti-CII IgG
Microtitre plates (96-well) were coated with 50 µl of
2 µg/ml CII dissolved in Tris-buffered saline overnight at
4°C. After blocking for 2 hours with 2% casein (200 µl),
wells were repeatedly washed with PBS/Tween and then
50 µl of 10-fold dilutions of mouse sera from 1/10 to
1/100 000 000 were applied to the wells and incubated
overnight at 4°C. Total anti-CII IgG and IgG isotypes were
quantitated using 50 µl of peroxidase conjugated sheep
antimouse IgG, IgG1 and IgG2a (The Binding Site) at a
dilution of 1/5000 with PBS/Tween. Signal was detected
as described above. Each plate included a standard curve
of a positive serum obtained from untreated CIA mice at
day 40, which was used to define arbitrary units of total
IgG, IgG1 and IgG2a anti-CII antibodies.
Measurement of IL-4 and IFN-γ by ELISA
Microtitre plates were coated with 50 µl of capture anti-
body for IL-4 (rat antimouse IL-4 used at 2 µg/ml; Pharmin-
gen, San Diego, CA, USA) or IFN-γ (rat antimouse IFN-γ
used at 5 µg/ml; Pharmingen), both antibodies were
diluted with 0.5 mol/l carbonate/bicarbonate buffer
(pH 9.6), and plates were incubated overnight at 4°C.
Plates were washed with PBS and then blocked with
200 µl of 2% casein solution in PBS for 1 hour at room
temperature. Plates were washed with PBS/Tween before
incubation of 50 µl of samples and standards (mIL-4
[10 ng/ml to 3 pg/ml] or IFN-γ [300 ng/ml to 100 pg/ml])
for 3 hours at room temperature. Plates were washed
extensively with PBS/Tween before incubation with 50 µl
biotinylated mouse monoclonal antibody to IL-4 (rat anti-
mouse IL-4 used at 0.5 µg/ml; Pharmingen) or IFN-γ (rat
antimouse IFN-γ used at 1 µg/ml; Pharmingen). Plates
were again washed and then incubated with streptavidin
biotinylated horseradish peroxidase complex (diluted
1 : 1000; Amersham Biosciences UK Ltd, Little Chalfont,
Bucks, UK). Signal was detected as described above and
the limits of detection for the IL-4 and IFN-γ ELISAs were
3 pg/ml and 100 pg/ml, respectively.
Statistical analysis
Descriptive statistics and significant differences between
groups were calculated using Student’s t-tests for two
samples data of unequal variance (Microsoft® Excel 98
software).
Results
Expression of dTNFR in vitro
Transient transfection of Cos-7 cells was used to demon-
strate expression of dTNFR from the construct pcdTNFR
(Fig. 2). A basal level of TNFR2 was also detected in the
control transfection of Cos-7 with pcDNA3, which indi-
cates that the ELISA cross-reacts with the monkey TNFR2
produced spontaneously by this cell line. We previously
found that this ELISA reacts with monkey TNFR2 (unpub-
lished data).
Expression of dTNFR from pGTRTT was determined in
transiently transfected Cos-7 cells. Induction of trans-
fected Cos-7 cells with doxycycline (1 µg/ml) for 48 hours
achieved expression levels of dTNFR from pGTRTT that
were equivalent to the levels produced from cells trans-
fected with pcdTNFR (Fig. 2). As previously demonstrated
for pGTRTL, there was some basal activity of the Ptet in
pGTRTT, with dTNFR expression detected in the absence
of doxycycline induction. As expected, the control vector
pGTRTEmpty expressed no dTNFR above background in
either the absence or presence of doxycycline.
Expression of luciferase following in vivo plasmid
injection and electroporation
Electroporation has been reported to enhance the trans-
fection efficiency of plasmid DNA delivered in vivo by
intramuscular injection [10]. In order to confirm this effect
in naïve DBA/1 mice, the constitutively expressing plasmid
pcLuc+ was injected intramuscularly and electroporated.
Measurement of luciferase expression 3 days later indi-
cated that electroporation enhanced transfection effi-
ciency, with expression levels 245-fold greater than
achieved with DNA injection alone (Fig. 3a).
The self-contained autoregulatory plasmid pGTRTL, which
was previously shown to function efficiently in vitro, was
assessed for function in vivo following delivery to naïve
DBA/1 mice. Expression of luciferase from pGTRTL was
compared with luciferase expression from the control
vectors pGCMV, pGmCMV and pGTL. In each case, after
DNA was injected and electroporated the mice were left
for 2 weeks; then those that were injected with pGTRTL
either were maintained non-induced with a drink of 10%
sucrose, or they were induced with doxycycline drinks pre-
pared in 10% sucrose at concentrations of 200 µg/ml or
2 mg/ml. After a further 2 weeks mice were killed and
expression levels of luciferase determined. Results in
Fig. 3a confirmed that regulated expression of luciferase
from pGTRTL is observed in vivo, with 43-fold and 27-fold
induction observed in groups that received doxycycline
drinks of 200 µg/ml and 2 mg/ml, respectively. Induced
levels of luciferase from pGTRTL with 200 µg/ml doxycy-
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cline exceeded the expression levels observed with
pGCMV by more than threefold. Interestingly, basal
expression of luciferase from pGTRTL was significantly
greater than from the control vectors pGmCMV and
pGTL.
The downregulation of luciferase expression from pGTRTL
in vivo was assessed in mice that were untreated for
2 weeks after DNA injection, then induced with doxycy-
cline (200 µg/ml) for 2 weeks, and then had doxycycline
removed for 3 days before terminating the experiment.
Fig. 3c illustrates that removal of doxycycline for 3 days
resulted in return to basal levels of luciferase expression
observed for the non-induced pGTRTL group, whereas a
group that continued to receive doxycycline for the extra
3 days maintained induced levels of luciferase expression.
Treatment of collagen-induced arthritis with pcdTNFR
after disease onset
Control plasmid pcDNA3 (n = 11) or the expression
plasmid pcdTNFR (n = 14) were delivered by intramuscu-
lar injection and electroporation to arthritic (clinical score
at least 0.5) DBA/1 mice on day 27 after CII immunization.
Clinical score and hind paw swelling was monitored and is
shown in Fig. 4a and 4b. The results indicate that there
was no therapeutic effect of pcTNFR treatment. The clini-
cal score of mice at the time of DNA delivery on day 27
was in the range 0.5–4, and a published study indicates
that the therapeutic outcome of TNF-α inhibition is related
to the level of disease activity when treatment is initiated in
Arthritis Research & Therapy    Vol 6 No 2 Gould et al.
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Figure 3
Constitutive and regulated luciferase expression in vivo. (a) Plasmid
pcLuc+ (15 µg) was injected intramuscularly into the right quadriceps
of six naïve DBA/1 mice. The muscle of three mice was then
electroporated (8 pulses, 200 V/cm, 20 ms duration, 2 Hz), and the
other three mice were untreated. Three days later the experiment was
terminated and muscle processed for measurement of luciferase.
Levels of luciferase are the mean of three animals and are normalized
for protein concentration of the muscle lysate. Vertical lines represent
standard error, and a significant difference (P ≤ 0.01) between the
luciferase level in the muscle of electroporated and non-electroporated
mice is indicated (*). (b) Plasmid DNA (15 µg) was injected
(intramuscularly) and electroporated in naïve DBA/1 mice. After
2 weeks GTRTL injected mice (n = 5 for all groups) were given 10%
sucrose (white bar), or doxycycline drinks (black bars) prepared in
10% sucrose at 200 µg/ml and 2 mg/ml for the subsequent 2 weeks.
Luciferase expression in muscle was determined in dissected muscle
and was compared with that in mice receiving the control plasmids
pGCMV, pGmCMV and pGTL. Significant differences between the
pGTRTL plus doxycycline groups and the non-induced pGTRTL group
(P ≤ 0.05) are indicated (*). (c) Downregulation of luciferase expression
from pGTRTL was assessed in a group of mice that had received
doxycycline 200 µg/ml for 2 weeks; they were switched to sucrose for
3 days, after which luciferase levels in muscle were compared with
those in groups that were non-induced or continuously induced for the
duration of the experiment. A significant difference between the
pGTRTL plus doxycycline group and the non-induced pGTRTL group
(P ≤ 0.05) is indicated (*), and a significant difference between the
pGTRTL doxycycline removed group and the pGTRTL doxycycline 200
group (P ≤ 0.05) is indicated ($). RLU, relative light unit.
Figure 2
Expression of dimeric human tumour necrosis factor receptor 2
(dTNFR) from pcdTNFR and pGTRTT transfected Cos-7 cells. Cos-7
cells plated in 12-well plates at 0.4 × 106/well were transiently
transfected with 2 µg of the constructs pGTRTT, pcdTNFR,
pGTRTEmpty and pcDNA3. Cells transfected with pGTRTT or
pGTRTEmpty were either cultured in normal media (lighter bars) or
media supplemented with doxycycline (1 µg/ml; darker bars). Levels of
human TNFR2 were measured in culture supernatants collected after
48 hours and are expressed as the mean of triplicate values, with
vertical lines representing the standard error.
mouse CIA [22]. Animals were therefore subdivided into
those that had a clinical score of 2 or less and those with
a higher clinical score at the time of DNA injection. In
terms of clinical score, a significant therapeutic effect of
pcdTNFR was observed in mice (n = 6) with lower disease
activity at the time of DNA injection, as compared with
those injected with pcDNA3 (n = 9), and no therapeutic
effect was observed in mice with a clinical score greater
than 2 when treatment (pcdTNFR, n = 8; pcDNA3, n = 2)
was initiated (Fig. 4c and 4e). Data for paw swelling also
illustrate a significant therapeutic effect of pcdTNFR in
mice with lower disease activity than in those that had
more established disease at the initiation of treatment
(Fig. 4d and 4f).
Inhibition of collagen-induced arthritis with dTNFR
expressed from pGTRTT delivered after disease onset
Animals injected with the plasmid pGTRTT on day 27 and
administered doxycycline (n = 17) developed significantly
reduced arthritis, as measured by paw thickness and clini-
cal score, when compared with control animals that
received pGTRTT but no doxycycline (n = 16) and animals
that received the control vector pGTRTEmpty and doxycy-
cline (n = 16; Fig. 5a and 5b). When therapeutic effect
was assessed on the basis of disease activity at the time
of DNA delivery, it was clear that animals with a clinical
score under 2 responded to pGTRTT plus doxycycline
treatment in terms both of clinical score and of hind paw
swelling (Fig. 5c and 5d). Where disease had progressed
to give a clinical score greater than 2 at the time of DNA
delivery, no benefit of pGTRTT plus doxycycline was
observed (Fig. 5e and 5f).
Levels of dTNFR in the serum of pGTRTT treated mice
was below the detection level of the ELISA (data not
shown), and no antihuman TNFR2 was detected in these
sera (data not shown), indicating that the dTNFR was not
immunogenic during the time frame of the experiment.
The average daily fluid intakes per mouse for the groups in
which the treated animals were housed were determined
at 3.6 ml, 3.1 ml and 3.4 ml for the pGTRTT plus doxycy-
cline, pGTRTT without doxycycline, and pGTRTEmpty
plus doxycycline treatment groups, respectively. The
average amount of doxycycline administered was therefore
720 µg in the pGTRTT treated group, which equates to
approximately 30 mg/kg doxycycline/day.
Immunological status of collagen-induced arthritis mice
was not altered by dTNFR treatment
The anti-CII antibody profile of mice treated with pGTRTT
with or without doxycycline and pGTRTEmpty was similar
at the end of the experiment for all groups (Table 1). In
addition, cytokine release from draining lymph node cells
in response to CII or ConA stimulation was also unaf-
fected by any treatment (Table 2).
Discussion
In the present study we demonstrated a therapeutic effect
of dTNFR in CIA when expressed from plasmid DNA
under the control of constitutive and regulated promoters.
Importantly, the therapeutic effect was achieved when
DNA was delivered after disease onset, and all of the
components for regulated expression were combined in a
single vector.
We confirmed in DBA/1 mice that electroporation
increases transfection efficiency in vivo following intra-
muscular injection of plasmid DNA, with transgene expres-
sion detected beyond 4 weeks from pGTRTL. In
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Figure 4
Effect of pcdTNFR on progression of collagen-induced arthritis.
Development of arthritis was monitored by (a, c and e) clinical score
and (b, d and f) hind paw swelling in DBA/1 mice. Treatment was
administered after onset of clinical arthritis. All mice injected with
pcdTNFR (; n = 16) and pcDNA3 (; n = 11) are depicted in panels
a and b; those with a clinical score less than 2 at the time of DNA
injection are presented in panels c and d; and those with a clinical
score above 2 when treatment was initiated are plotted in panels e
and f. Significant differences between the pcdTNFR and pcDNA3
group (P ≤ 0.05) are indicated (*).
agreement with other studies using mice, these observa-
tions indicate that there is long-term persistence of
plasmid DNA [10], and expression of the transgene
luciferase [10] and rtTA [23] encoded by the autoregula-
tory plasmid. Regulation from pGTRTL in vivo is compara-
ble to in vitro function [19], as demonstrated by the
43-fold increase in luciferase expression induced by
2 weeks of doxycycline induction, and return to basal
expression 3 days after removal of doxycycline. Interest-
ingly, the basal expression from pGTRTL was elevated
compared with pGTL in vivo, whereas the basal expres-
sion from the two vectors was similar in cultured fibro-
blasts [19], which may indicate an effect that is related to
expression in skeletal muscle. Improvements in the tetracy-
cline system have led to the development of tetR targeted
repressors such as tetR–KRAB [24] and tTS [25], which
have been shown to reduce efficiently basal expression
from the Ptet regulated promoters in vitro and when
codelivered to skeletal muscle [26,27]. Incorporating the
tetR–KRAB gene into the self-contained plasmid would
reduce basal expression and increase the magnitude of
regulation, as was recently achieved with an adenoviral
vector [28].
According to data obtained in clinical trials, transfection of
human skeletal muscle with injected plasmid DNA does
not appear to be as efficient as in mice because only
short-term transgene expression has been demonstrated
[29]. Enhanced transfection efficiency by electroporation
has yet to be conducted in humans, but observations with
primates indicate a beneficial effect [10]. The tetracycline
gene regulatory system has also been demonstrated to
function in primates, but there is evidence of immuno-
genicity in this species [30]. Although the components of
the system may also be immunogenic in humans, further
research will be needed to determine whether regulated
expression of an immunomodulatory cytokine enables
transfected cells to evade detection by the immune
system.
Constitutive expression of therapeutic genes has been uti-
lized extensively and successfully in experimental gene
therapy. However, for clinical application regulated pro-
moter systems are more flexible because they enable the
level of expression to be controlled and provide a means
by which to terminate gene expression. These features are
likely requirements for gene therapy application in chronic
relapsing conditions such as RA. Although the present
study demonstrates the effectiveness of the pGTRTT
autoregulated vector, the full utility was not harnessed
because dTNFR was continuously induced. More strin-
gent examination requires the use of chronic arthritis
models such as CIA in Vβ12 T-cell receptor transgenic
mice [31] and use of therapeutic molecules that actually
reverse established disease, for example IL-4 [32] and
IL-1 inhibitors [22,33].
In the present study the therapeutic effect of dTNFR was
clearly demonstrated in CIA when expressed from plas-
mids with constitutive or regulated promoters, but in both
cases the therapeutic effect was related to the disease
severity at the time of DNA injection. The first reports of
anti-TNF-α treatment by protein therapy in CIA indicated
that therapeutic effect was observed when anti-TNF-α
treatment was initiated before disease onset [34,35] or
immediately after onset [35]. The therapeutic effect of anti-
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Figure 5
Gene therapy treatment of collagen-induced arthritis (CIA) with
regulated expression of dimeric human tumour necrosis factor
receptor 2 (dTNFR). Progression of CIA was monitored by clinical
score (a, c and e) and hind paw swelling (b, d and f) in groups that
received pGTRTEmpty plus doxycycline (; n = 16), pGTRTT without
doxycycline (; n = 16) and pGTRTT plus doxycycline (; n = 17).
Treatment was administered after onset of clinical arthritis. All treated
animals are illustrated in panels a and b; those with a clinical score of
2 or less at the time of DNA injection (day 27) are illustrated in panels
c and d; and animals with a clinical score greater than 2 at the start of
treatment are depicted in panels e and f. Significant differences
between the pGTRTT plus doxycycline and the pGTRTT without
doxycycline groups are indicated (*P < 0.05, **P < 0.02 and
***P < 0.01).
TNF-α in CIA was later shown to relate directly to the
stage of CIA development at the time treatment was initi-
ated, with maximum effect achieved when treatment was
started just after disease onset. The effect was less when
administered 2 days after onset and it was ineffective
when treatment was started 7 days after onset [22].
Essentially, where disease activity was lower anti-TNF-α
was beneficial, but when disease was more advanced
TNF-α inhibition was ineffective. This is akin to observa-
tions in our gene therapy experiments. By contrast, anti-
TNF-α therapy causes a reversal of chronic symptoms in a
large proportion of RA patients, which clearly highlights a
differential outcome from anti-TNF-α therapy in CIA and
human disease.
The tetracycline system has previously been utilized in CIA
gene therapy for regulated expression of vIL-10 [27,36]. In
one study [36] regulated expression of vIL-10 was
achieved by injection of two adeno-associated virus
vectors intramuscularly before immunization of DBA/1
mice, and doxycycline administration started 23 days after
immunization. The study conducted by Perez and cowork-
ers [27] involved coinjection of a single plasmid from
which vIL-10 was regulated, along with a plasmid encod-
ing the transcriptional silencer tTS. Doxycycline and plas-
mids (intramuscular and electroporated) were both
delivered before onset of disease and resulted in a
modest delay in onset and reduced incidence of arthritis.
Doxycycline is reported to have direct effects on inflamma-
tory processes, which theoretically could be of direct
benefit in the treatment of arthritis. In vitro studies have
shown that doxycycline inhibits bone and cartilage break-
down [37], inhibits matrix metalloproteinases (particularly
the activity of matrix metalloproteinase-13 and -8 against
CII [38]), increases inducible nitric oxide synthase mRNA
degradation [39], and induces Fas/Fas ligand mediated
apoptosis of activated T cells [40]. However, these effects
of doxycycline in general have a 50% inhibitory concentra-
tion in excess of 10 µg/ml, whereas maximal activation of
the Ptet occurs at a concentration of 1 µg/ml. Indeed, no
beneficial effect of doxycycline treatment with the control
vector pGTRTEmpty was evident in this study, and a
recent clinical trial showed no benefit of doxycycline treat-
ment of RA patients [41]. However, the tetracycline ana-
logue minocycline administered at a similar concentration
(800 µg/ml) to that used this study was beneficial in adju-
vant arthritis and CIA in rats [42].
When anti-TNF-α treatments were initiated before onset of
disease in CIA and in transfer models of arthritis, effects
have been observed on disease severity [4,34,35,43,44].
Changes in immune response were also noted, including
reduced proinflammatory cytokine production, anti-CII anti-
body levels in sera [4], and changes in anti-CII
immunoglobulin isotype ratio [45,46], indicating a down-
regulation of the T-helper-1 response.
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Table 1
Anticollagen II antibodies in mice with collagen-induced arthritis
Anti-CII antibodies
Treatment Total IgG1 IgG1 IgG2a IgG2a : IgG1 ratio
GTRTEmpty + doxycycline 0.64 ± 0.11 2.0 ± 0.7 1.6 ± 0.3 1.3 ± 0.4
GTRTT – doxycycline 1.1 ± 0.4 1.7 ± 0.5 1.5 ± 0.5 1.4 ± 0.3
GTRTT + doxycycline 1.1 ± 0.3 1.6 ± 0.3 1.3 ± 0.2 1.4 ± 0.4
Results are presented from at least six animals in each group. Anti-CII IgG levels in sera collected at the end of the experiment (day 40) was
determined by ELISA, with values expressed relative to those obtained for a pooled sample from untreated mice at the same time point. CII,
collagen type II.
Table 2
Cytokine release from draining lymph node cells of collagen-induced arthritis mice
Cytokine release from DLN cells
IFN-γ (ng/ml): IFN-γ (ng/ml): IL-4 (pg/ml): IL-4 (pg/ml):
Treatment 48 hour CII 48 hour ConA 48 hour CII 48 hour ConA
GTRTEmpty + doxycycline 0.41 ± 0.03 4.2 ± 1.1 11.9 ± 3.2 33.2 ± 8.8
GTRTT – doxycycline 0.66 ± 0.15 2.4 ± 0.8 6.4 ± 1.5 24.4 ± 6.7
GTRTT + doxycycline 0.49 ± 0.04 2.8 ± 0.9 9.0 ± 1.6 21.5 ± 2.4
Results are presented from at least six animals in each group. Cytokine release from draining lymph node (DLN) cells was induced by 48 hours of
stimulation with CII or ConA and was measured by ELISA. CII, collagen type II.
When gene therapy has been started at the onset of
disease, the therapeutic effects of anti-TNF-α have been
less consistent. Expression of a dimeric chimeric human
TNFR1–IgG fusion protein from adenovirus was effective
in a rat CIA model when delivered intravenously after
onset (low level) of disease, but it was ineffective when
delivered intra-articularly [43]. In mouse CIA, intravenous
administration of adenovirus encoding the same dimeric
TNFR1 molecule at onset ameliorated disease develop-
ment for 10 days and was followed by rebound exacer-
bated disease [47]. Injection of retrovirus encoding
TNFR1–IgG peri-articularly at the onset of disease inhib-
ited its progression [48]. Injection of retrovirally trans-
duced syngeneic fibroblasts encoding dTNFR at onset of
CIA did not prevent disease development [4]. These previ-
ous studies used viral vectors, and in this regard our study
is the first to observe a therapeutic effect with a TNF-α
inhibitor expressed from plasmid constructs.
Few studies have examined the effects of anti-TNF-α on the
immune system when treatment commenced at or after the
onset of CIA. Expression of dTNFR from fibroblasts injected
at CIA onset did not alter anti-CII levels [4], while expression
of TNFR1–immunoglobulin following injection (peri-articu-
larly) of encoding retrovirus at onset in arthritic paws has
been reported to reduce anti-CII levels, particularly IgG2a, at
7 days after onset [48]. We were unable to show any effect
of dTNFR treatment on anti-CII levels or cytokine expression
from stimulated draining lymph node cells. Although we
examined immunological markers at a similar time point as
did Muhkerjee and coworkers [48], we used different TNF-α
inhibitors, vectors and routes of delivery, and we initiated
treatment after disease onset.
The observation that expression of dTNFR for 13 days in
the CIA experiments was not immunogenic is encourag-
ing. In RA patients there has been no report of immuno-
genicity against Etanercept®, which also contains the
extracellular domain of the human TNFR2. By contrast,
expression of TNFR1–IgG encoded from adenovirus in
mouse CIA led to the development of autoantibodies to
mouse TNFR1 [47]. There was some evidence that these
antibodies had agonistic TNF-α activity in vitro, and the
immunogenicity of the TNFR1–IgG was associated with
the rebound exacerbation of disease that was observed.
The overall picture that emerges is that before disease
onset inhibition of TNF-α can inhibit disease development
by targeting the immune response. But after onset of
disease the target for TNF inhibition is to block the
cascade of inflammatory cell recruitment and for optimal
effect the inhibitory molecule should be delivered as soon
after disease onset as possible.
This study illustrates the potential for performing gene
therapy with a single injection of regulated vector in CIA.
Improvements in plasmid delivery and gene regulation may
permit adoption of a similar therapeutic approach in RA
patients in the future.
Conclusion
In the present study we inhibited disease progression in
established CIA with dTNFR expressed from plasmid DNA
in a constitutive or regulated manner. Response to anti-
TNF-α therapy occurs in a large proportion of RA patients.
However, in CIA inhibition of TNF-α is less potent. In the
study we showed that inhibition of disease progression, by
a plasmid encoding dTNFR, is mainly observed when the
arthritis score is low at the start of treatment. Regulated
vectors are powerful tools in gene therapy but will require
stringent long-term testing in chronic models of disease in
order to demonstrate their full potential. Plasmid delivery
of therapeutic molecules such as TNF-α inhibitors repre-
sents a feasible and simple gene therapy approach for RA
treatment and demands further improvements in gene reg-
ulation and methods of delivery.
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